II. Definitions
- Opiate
- Opioids
- Includes Opiates (naturally occurring)
- Semi-synthetic Opioids (structurally similar to Opiates)
- Examples: Hydrocodone, Oxycodone, Hydromorphone, Oxymorphone
- Synthetic Opioids
- Examples: Methadone, Buprenorphine, Meperidine, Fentanyl, Tramadol
III. Adverse Effects
- See Opioid Adverse Effect
- See Opioid Overdose
- See Opioid Abuse
- See Opioid Withdrawal
IV. Pharmacology: Metabolism of Opioids
- Common Metabolites
- Codeine: Metabolizes to Hydrocodone and Morphine
- Heroin: Metabolizes to 6-acetylmorphine (6-MAM) and then to Morphine
- Morphine and Hydrocodone: metabolize to Hydromorphone
- Hydrocodone: Metabolizes to Dihydrocodeine
- Oxycodone: Metabolizes to Oxymorphone
- Renal dysfunction
- Hepatic dysfunction
- References
- Johnson (2007) Opioid Safety in Patients With Renal or Hepatic Dysfunction, Pain Treatment Topics
V. Pharmacology: Mechanism
- Opiate receptor Agonists in-vivo are triggered by stress and pain
- Opium derivatives (e.g. Morphine) and synthetics mimic endogenous Opioid-like agents
- CNS Opiate receptor binding results in analgesia and euphoria
- Receptor types include mu, kappa and delta receptors
- Endogenous Opioid-like agents
- Endorphins
- Enkephalins
- Dynorphins
- Endogenous Opioids are synthesized from Protein precursors
- Pro-opiomelanocortin (POMC, also a precursor for ACTH and Melanocyte Stimulating Hormone)
- Proenkephalin
- Prodynorphin
- Opium derivatives (e.g. Morphine) and synthetics mimic endogenous Opioid-like agents
- Opiate receptors are concentrated in the periqueductal gray matter (as well as other CNS regions)
- Opioids bind Neuron membrane receptors
- Cells become hyperpolarized
- Charge difference increases between intracellular and extracellular fluid
- Decreases likelihood of Neuron activation (firing) in response to a given Action Potential
- Sensory Neurons decrease activity
- Results in fewer afferent, sensory signals returning to CNS
- Pain Sensation is therefore reduced
- Overall Opiate Receptor Agonist Effects
- Analgesia
- Sedation
- Respiratory depression
- Gastrointestinal side effects (Nausea, Vomiting, ileus, Constipation)
- Miosis
- Antidiuretic Hormone release
VI. Approach: Quantity Prescribed
VII. Precautions: General
- Informed Consent for Opioid Prescription
- Pregnancy
- Neural Tube Defects if Opioids used in early pregnancy
- Newborn Opioid Withdrawal (neonatal abstinence syndrome) if maternal Chronic Opioid use
- No evidence of Tramadol safety
- Buprenorphine (without Naloxone) or Methadone may be used for pregnant women with Opioid Use Disorder
- (2017) Presc Lett 24(11): 64
- (2017) Obstet Gynecol 130(2):e81-e94 +PMID:28742676 [PubMed]
- Reddy (2017) Obstet Gynecol 130(1):10-28 +PMID:28594753 [PubMed]
- Respiratory Depression
- Exercise caution in comorbid COPD, Obstructive Sleep Apnea and other respiratory disorders
- Avoid in combination with CNS Depressants (e.g. Benzodiazepines, Z-Drugs)
VIII. Precautions: Ineffective Oral Opioids (Not recommended)
-
Darvocet N-100 (Acetaminophen 650, Propoxyphene 100)
- Dose: 1 PO q4-6 hours
- Not available in U.S. as of 2007-2010
- Not recommended due to low efficacy and toxicity risk
-
Tylenol #3 (Acetaminophen 300, Codeine 30)
- Dose: 1-2 PO q4-6 hours
- Avoid due to low efficacy and increased toxicity risk
IX. Precautions: Metabolism and Drug Interactions
- Severe liver disease (Cirrhosis)
- Fentanyl is preferred (Pharmacokinetics are not significantly affected)
- Consider oral Opioid dose reduction to 50% and increasing dosing frequency (due to decreased first pass metabolism)
- Avoid Morphine (increased Bioavailability and decreased clearance)
- Renal Failure (or Chronic Kidney Disease 4 or 5)
- Elderly
- Increased adverse effect risk (altered Pharmacokinetics, Polypharmacy, Fall Risk)
- Fewer Analgesic alternatives (avoid NSAIDS)
- Avoid Tramadol
- Start oral Opioids at 25 to 50% of normal dose
-
Serotonin Syndrome
- Risk with serotonergic Opioids (e.g. Tramadol, Fentanyl, Meperidine, Methadone)
- Avoid combining with other serotonergic agents (e.g. SSRIs)
- Variable metabolism of oral Opioids
- Most oral Opioids are metabolized to active form (e.g. Morphine) by Cytochrome P450 2D6 (CYP2D6)
- Ultrarapid CYP2D6 Metabolizers
- Accounts for 10% of caucasians (may be as high as 30% in some races)
- Risk of a rapid conversion to toxic levels of active Opioid (e.g., Morphine)
- Slow CYP2D6 Metabolizers
- Accounts for 10% of caucasians (or 3% of other races)
- Renders the oral Opioids less effective in slow metabolizing patients
- CYP3A4 Inhibitors (e.g. Itraconazole, Ritonavir)
- May increase levels of Hydrocodone, Oxycodone, Fentanyl
- References
- (2024) Presc Lett 31(6): 35
- (2012) Presc Lett 19(6): 33
- Crews (2012) Clin Pharmacol Ther 91:321-6 [PubMed]
X. Precautions: Iatrogenic Opioid Overdose prevention
- Avoid repeat intramuscular Opioid injection
- Risk of dose stacking and secondary CNS/Respiratory depression (esp. Dilaudid)
- Titrate dosing to pain while exercising caution in the elderly and Opioid naive
- See Dilaudid below for specific precautions
- Decrease dose to 50% in the elderly, hepatic insufficiency, Renal Insufficiency
- Opioid tolerant patients may still experience respiratory depression on typical Opioid doses
- Exercise caution when combining CNS Depressants (e.g. Opioids and Benzodiazepines)
- Long-acting Opioids for non-cancer Chronic Pain are associated with significantly increased mortality
- References
XI. Medications: Acute pain IV Opioids (equivalent to Demerol 50 mg IV)
-
Fentanyl 50 mcg IV (25 mcg IV in elderly)
- Preferred agent in Renal Insufficiency
- Onset <1 minute
- Peaks 2 to 5 minutes
- Duration 30 to 60 minutes
-
Morphine 4 mg IV (2 mg IV in elderly)
- Onset 1 to 2 minutes
- Peaks 3 to 5 minutes
- Duration 1 to 2 hours
-
Hydromorphone (Dilaudid)
- Onset 5 to 15 minutes
- Peaks 10 to 20 minutes
- Duration 2 to 4 hours
- Moderate pain: 0.5 mg IV
- Start with 0.2 to 0.3 mg IV in the elderly or Opioid naive
- May repeat every 15 to 30 minutes up to 3 doses in the emergency department
- Spread interval to every 2-3 hours on the hospital ward
- Opioid tolerant or severe pain: Start with 1 mg IV
- Dilaudid triggers greater euphoria than Fentanyl or Morphine (higher risk of drug seeking and abuse)
- Dilaudid is a high potency Opioid (1 mg is equivalent to up to 10 mg Morphine)
- Most iatrogenic Opioid Overdoses have occurred with Hydromorphone (Dilaudid)
XII. Medications: Oral Opioids by strength
- Weak Opioids (WHO Step 2)
- Vicodin (Hydrocodone 5, Acetaminophen 500)
- Dose: 1-2 PO q4-6 hours
- Hydrocodone 10 mg equivalent to Codeine 60-80 mg
- Vicoprofen (Hydrocodone 7.5, Ibuprofen 200)
- Dose: 1-2 PO q4-6 hours
- Tramadol (Ultram)
- Vicodin (Hydrocodone 5, Acetaminophen 500)
- Strong Opioids (WHO Step 3)
- Oxycodone
- Adults (and over age 12 years) 5-10 mg every 4-6 hours as needed
- Child: 0.05 to 0.3 mg/kg/dose (up to 10 mg) every 4-6 hours as needed
- Percocet (Acetaminophen 325, Oxycodone 5)
- Dose: 1 PO q6 hours (adults)
- Hydromorphone (Dilaudid)
- Dose: 2 mg orally every 4-6 hours
- Morphine Sulfate (MSIR, MS Contin)
- Fast Release: 15 to 30 mg orally every 4 hours
- Sustained Release (MS Contin): 30 mg orally every 8-12 hours
- Fentanyl Lollipop (100 ug, 200 ug, 300 ug, 400 ug)
- Dose: 5 to 15 ug/kg (maximum 400 ug)
- Methadone (Dolophine)
- Dose: 15 to 60 mg orally every 6 to 8 hours
- Oxycodone
XIII. Medications: Oral Opioids by duration
- Short acting Opioids
- Codeine (not recommended)
- Onset 30 to 60 minutes
- Duration 4 to 6 hours
- Tramadol (not recommended)
- Onset 1 hour
- Duration 4 to 6 hours
- Hydrocodone (e.g. Vicodin orally every 6 hours)
- Onset 30 to 60 minutes
- Duration 4 to 6 hours
- Oxycodone IR (e.g. Percocet orally every 6 hours)
- Onset 10 to 15 minutes
- Duration 3 to 6 hours
- Morphine Sulfate IR (e.g. MSIR 10 mg orally every 4 hours)
- Onset 30 minutes
- Peaks 1 hour
- Duration 3 to 5 hours
- Hydromorphone (e.g. 4 mg orally every 4 hours)
- Onset 15 to 30 minutes
- Peaks 30 to 60 minutes
- Duration 3 to 4 hours
- Codeine (not recommended)
- Long acting Opioids
XIV. Medications: MME - Morphine Equivalent Opioid Doses
XV. Medications: Transdermal Opioid
XVI. Medications: Transmucosal Opioid
XVII. Medications: Rectal Opioids
XVIII. Medications: By origin (natural Opiates, semi-sythetic and synthetic Opioids)
- Naturally occurring Opiates (opium poppy derivatives, subset of Opioids)
- Semi-synthetic Opioids (structurally similar to Opiates)
- Hydrocodone
- Oxycodone
- Hydromorphone
- Oxymorphone
- Synthetic Opioids
XIX. Medications: Opioid Abuse deterrents (e.g. Tamper resistant)
- Precautions
- Abuse deterrents are inconsistent among products
- Long-acting Hydrocodone (Zohydro) is not tamper resistant
- Abuse deterrents are not shown to reduce abuse
- abuse deterrent may simply offset abuse to other substances (e.g. Heroin)
- Abuse deterrents increase Opioid costs up to four fold
- Abuse deterrents are inconsistent among products
- Agents with abuse deterrents
- Opioids with abuse Antagonists
- Buprenorphine with Naloxone (Suboxone, Zubsolv)
- Opioids with tamper resistance (e.g. break into clumps when crushed or thick gel when wet)
- Long-Acting Oxycodone (Oxycontin)
- Extended Release Hydromorphone (Exalgo)
- Implantable Opioids
- Buprenorphine implant (Probiphine)
- Opioids with abuse Antagonists
- References
- (2014) Presc Lett 21(5): 28
XX. Medications: Adjunctive
- Alternative non-Opioids
- Stool Softeners or Laxatives
XXI. References
- Dachs (2003) AAFP Board Review, Seattle
- Hipskind and Kamboj (2016) Crit Dec Emerg Med 30(10): 15-23
- Velasco and Kiel (2023) Crit Dec Emerg Med 37(1): 4-9
- (2000) Tarascon Pocket Pharmacopoeia
- (2000) Med Lett Drugs Ther 42(1085):73-8 [PubMed]